Enfortumab Vedotin and Pembrolizumab in Untreated Advanced Urothelial Cancer.
Thomas PowlesBegoña P ValderramaShilpa GuptaJens BedkeEiji KikuchiJean Hoffman-CensitsGopa IyerChristof VulstekeSe Hoon ParkSang Joon ShinDaniel CastellanoGiuseppe FornariniJian-Ri LiMahmut GümüşNataliya MarYohann LoriotAude FléchonIgnacio DuranAlexandra DrakakiSujata NarayananXuesong YuSeema GorlaBlanca Homet MorenoMichiel S van der Heijdennull nullPublished in: The New England journal of medicine (2024)
Treatment with enfortumab vedotin and pembrolizumab resulted in significantly better outcomes than chemotherapy in patients with untreated locally advanced or metastatic urothelial carcinoma, with a safety profile consistent with that in previous reports. (Funded by Astellas Pharma US and others; EV-302 ClinicalTrials.gov number, NCT04223856.).
Keyphrases
- locally advanced
- squamous cell carcinoma
- hodgkin lymphoma
- rectal cancer
- advanced non small cell lung cancer
- neoadjuvant chemotherapy
- phase ii study
- radiation therapy
- small cell lung cancer
- high grade
- urinary tract
- epidermal growth factor receptor
- adverse drug
- adipose tissue
- metabolic syndrome
- lymph node
- glycemic control
- tyrosine kinase
- double blind